Male & female (non-pregnant, non-lactating, post-menopausal, surgically sterilized, or practicing a reliable <br/ >method of birth control during the duration of the study) patients with ages ranging from 18 to 65 years (both inclusive). <br/ > <br/ >Clinically stable condition for at least 6 months before enrollment. <br/ > <br/ >Confirmed diagnosis of moderate COVID-19 symptoms demonstrated by: <br/ > <br/ >Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens. <br/ > <br/ >Presence of dyspnea and/or hypoxia, fever, cough, including SpO2 < 93% (range 90-93%) on room air, Respiratory Rate > 24 and < 30 breaths per minute. Patients with SpO2 < 90% to be excluded from the study. <br/ > <br/ >Signs of pneumonia (lung injury/lung involvement) confirmed by Chest X-Ray at the time of study entry. <br/ > <br/ >Disease severity score between Grade 4 to 5 on the WHO 9-point ordinal scale & patient requires <br/ >hospitalization for management of the disease. <br/ > <br/ >Within 7 days from symptom onset or within 72 hours of laboratory diagnosis of SARS-CoV2 via RT-PCR test. <br/ > <br/ >Able to take oral tablets at the time of study entry and agree not to participate in any other study for <br/ >duration of participation in this study. <br/ > <br/ >Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent then the same should be obtained from a legally acceptable representative (LAR). <br/ >

Male & female (non-pregnant, non-lactating, post-menopausal, surgically sterilized, or practicing a reliable <br/ >method of birth control during the duration of the study) patients with ages ranging from 18 to 65 years (both inclusive). <br/ > <br/ >Clinically stable condition for at least 6 months before enrollment. <br/ > <br/ >Confirmed diagnosis of moderate COVID-19 symptoms demonstrated by: <br/ > <br/ >Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens. <br/ > <br/ >Presence of dyspnea and/or hypoxia, fever, cough, including SpO2 < 93% (range 90-93%) on room air, Respiratory Rate > 24 and < 30 breaths per minute. Patients with SpO2 < 90% to be excluded from the study. <br/ > <br/ >Signs of pneumonia (lung injury/lung involvement) confirmed by Chest X-Ray at the time of study entry. <br/ > <br/ >Disease severity score between Grade 4 to 5 on the WHO 9-point ordinal scale & patient requires <br/ >hospitalization for management of the disease. <br/ > <br/ >Within 7 days from symptom onset or within 72 hours of laboratory diagnosis of SARS-CoV2 via RT-PCR test. <br/ > <br/ >Able to take oral tablets at the time of study entry and agree not to participate in any other study for <br/ >duration of participation in this study. <br/ > <br/ >Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent then the same should be obtained from a legally acceptable representative (LAR). <br/ >

Male & female (non-pregnant, non-lactating, post-menopausal, surgically sterilized, or practicing a reliable <br/ >method of birth control during the duration of the study) patients with ages ranging from 18 to 65 years (both inclusive). <br/ > <br/ >Clinically stable condition for at least 6 months before enrollment. <br/ > <br/ >Confirmed diagnosis of moderate COVID-19 symptoms demonstrated by: <br/ > <br/ >Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens. <br/ > <br/ >Presence of dyspnea and/or hypoxia, fever, cough, including SpO2 < 93% (range 90-93%) on room air, Respiratory Rate > 24 and < 30 breaths per minute. Patients with SpO2 < 90% to be excluded from the study. <br/ > <br/ >Signs of pneumonia (lung injury/lung involvement) confirmed by Chest X-Ray at the time of study entry. <br/ > <br/ >Disease severity score between Grade 4 to 5 on the WHO 9-point ordinal scale & patient requires <br/ >hospitalization for management of the disease. <br/ > <br/ >Within 7 days from symptom onset or within 72 hours of laboratory diagnosis of SARS-CoV2 via RT-PCR test. <br/ > <br/ >Able to take oral tablets at the time of study entry and agree not to participate in any other study for <br/ >duration of participation in this study. <br/ > <br/ >Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent then the same should be obtained from a legally acceptable representative (LAR). <br/ >

Male & female (non-pregnant, non-lactating, post-menopausal, surgically sterilized, or practicing a reliable <br/ >method of birth control during the duration of the study) patients with ages ranging from 18 to 65 years (both inclusive). <br/ > <br/ >Clinically stable condition for at least 6 months before enrollment. <br/ > <br/ >Confirmed diagnosis of moderate COVID-19 symptoms demonstrated by: <br/ > <br/ >Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens. <br/ > <br/ >Presence of dyspnea and/or hypoxia, fever, cough, including SpO2 < 93% (range 90-93%) on room air, Respiratory Rate > 24 and < 30 breaths per minute. Patients with SpO2 < 90% to be excluded from the study. <br/ > <br/ >Signs of pneumonia (lung injury/lung involvement) confirmed by Chest X-Ray at the time of study entry. <br/ > <br/ >Disease severity score between Grade 4 to 5 on the WHO 9-point ordinal scale & patient requires <br/ >hospitalization for management of the disease. <br/ > <br/ >Within 7 days from symptom onset or within 72 hours of laboratory diagnosis of SARS-CoV2 via RT-PCR test. <br/ > <br/ >Able to take oral tablets at the time of study entry and agree not to participate in any other study for <br/ >duration of participation in this study. <br/ > <br/ >Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent then the same should be obtained from a legally acceptable representative (LAR). <br/ >